Loading…
Reported covered position: General Counsel, Senate Committee on Health, Education, Labor, & Pensions (HELP) (2015-2019); Counsel, Senate HELP Committee (2015); Counsel, Sen. Chambliss (2013-2015); Regional Rep., Sen. Chambliss (2012-2013); Press Intern, Sen. Chambliss (2007)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Mikaela Naylon Give Kids a Chance Act
Client: NEURELIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Policy issues related to federal regulation of the healthcare industry and rare diseases, including the Give Kids a Chance Act (119th, H.R. 1262 / S. 932) and the Retaining Access and Restoring Exclusivity (RARE) Act (118th, H.R. 7383 / S. 1214).
Small Biotech Innovation Act
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
SPYRE THERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · Q3
Issues related to monoclonal antibody products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEW YORK BLOOD CENTER ENTERPRISES via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · Q3
Source: Senate LDA
| CALBRIGHT COLLEGE |
| 13 |
| 2023–2026 |
| ADAPTIVE BIOTECHNOLOGIES | 11 | 2021–2023 |
| ALVOGEN | 10 | 2021–2023 |
| BAYLOR UNIVERSITY | 8 | 2021–2023 |
| BIOTELEMETRY, INC. | 8 | 2022–2023 |
| GRIFOLS SHARED SERVICES NORTH AMERICA, INC. | 8 | 2023–2024 |
| PERRIGO COMPANY PLC | 8 | 2022–2024 |
| SOCIAL FINANCE, INC. | 8 | 2022–2023 |
| CHILDREN'S HOSPITAL OF THE KING'S DAUGHTERS | 5 | 2021–2022 |
| CHILDRENS HEALTH SYSTEM OF TEXAS | 5 | 2021–2022 |
| NEURELIS INC | 5 | 2024–2026 |
| NOVO NORDISK A S | 5 | 2024–2025 |
| RECORDATI RARE DISEASES INC. | 5 | 2025–2026 |
| Spyre Therapeutics, Inc. | 5 | 2025–2026 |
| ESTEVE PHARMACEUTICALS, S.A. | 4 | 2026 |
| INDUCTIVEHEALTH INFORMATICS | 4 | 2023 |
| NEW YORK BLOOD CENTER ENTERPRISES | 4 | 2026 |
| PHARMACOSMOS THERAPEUTICS INC. | 4 | 2021–2022 |
| PHARMAESSENTIA USA CORPORATION | 4 | 2024 |
| SUMITOMO PHARMA AMERICA, INC. | 4 | 2026 |
| NEURALINK CORP. | 3 | 2026 |
| ORGANOGENESIS | 2 | 2022 |
| REGENERON PHARMACEUTICALS, INC. | 2 | 2022–2026 |
| RIGEL PHARMACEUTICALS INC. | 2 | 2021 |
| UNICYCIVE THERAPEUTICS INC. | 2 | 2026 |
| ALASKA - ALBERTA RAILWAY DEVELOPMENT CORPORATION | 1 | 2021 |
| EVOENDO, INC. | 1 | 2022 |
Small Biotech Innovation Act
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Small Biotech Innovation Act
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Treat and Reduce Obesity Act of 2025
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Treat and Reduce Obesity Act of 2025
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Treat and Reduce Obesity Act of 2025
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Stem Cell Therapeutic and Research Reauthorization Act of 2025
Client: NEW YORK BLOOD CENTER ENTERPRISES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to HRSA's regulation of cord blood storage and the Stem Cell Therapeutic and Research Reauthorization Act (HR5160/S4109).
Stem Cell Therapeutic and Research Reauthorization Act of 2025
Client: NEW YORK BLOOD CENTER ENTERPRISES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to HRSA's regulation of cord blood storage and the Stem Cell Therapeutic and Research Reauthorization Act (H.R. 5160/S. 4109).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Treat and Reduce Obesity Act of 2025
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Treat and Reduce Obesity Act of 2025
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Treat and Reduce Obesity Act of 2025
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Stem Cell Therapeutic and Research Reauthorization Act of 2026
Client: NEW YORK BLOOD CENTER ENTERPRISES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to HRSA's regulation of cord blood storage and the Stem Cell Therapeutic and Research Reauthorization Act (H.R. 5160/S. 4109).
Stem Cell Therapeutic and Research Reauthorization Act of 2026
Client: NEW YORK BLOOD CENTER ENTERPRISES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to HRSA's regulation of cord blood storage and the Stem Cell Therapeutic and Research Reauthorization Act (HR5160/S4109).
Policy issues related to federal regulation of the healthcare industry and rare diseases, including the Give Kids a Chance Act (119th, H.R. 1262 / S. 932) and the Retaining Access and Restoring Exclusivity (RARE) Act (118th, H.R. 7383 / S. 1214).
Policy issues related to federal regulation of the healthcare industry and rare diseases, including the Give Kids a Chance Act (119th, H.R. 1262 / S. 932) and the Retaining Access and Restoring Exclusivity (RARE) Act (118th, H.R. 7383 / S. 1214).
Policy issues related to federal regulation of the healthcare industry and rare diseases, including the Give Kids a Chance Act (119th, H.R. 1262 / S. 932) and the Retaining Access and Restoring Exclusivity (RARE) Act (118th, H.R. 7383 / S. 1214).
Mikaela Naylon Give Kids a Chance Act
Client: NEURELIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Policy issues related to federal regulation of the healthcare industry and rare diseases, including the Give Kids a Chance Act (119th, H.R. 1262 / S. 932) and Retaining Access and Restoring Exclusivity (RARE) Act (118th, H.R. 7383 / S. 1214).
Small Biotech Innovation Act
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Small Biotech Innovation Act
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Small Biotech Innovation Act
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Treat and Reduce Obesity Act of 2025
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Treat and Reduce Obesity Act of 2025
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Treat and Reduce Obesity Act of 2025
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Treat and Reduce Obesity Act of 2025
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Policy issues related to federal regulation of the healthcare industry and rare diseases, including the Give Kids a Chance Act (119th, H.R. 1262 / S. 932) and Retaining Access and Restoring Exclusivity (RARE) Act (118th, H.R. 7383 / S. 1214).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
Policy issues related to federal regulation of the healthcare industry and rare diseases, including the Give Kids a Chance Act (119th, H.R. 1262 / S. 932) and Retaining Access and Restoring Exclusivity (RARE) Act (118th, H.R. 7383 / S. 1214).
Policy issues related to federal regulation of the healthcare industry and rare diseases, including the Retaining Access and Restoring Exclusivity (RARE) Act (118th, H.R. 7383 / S. 1214).
Policy issues related to federal regulation of the healthcare industry and rare diseases, including the Give Kids a Chance Act (119th, H.R. 1262 / S. 932) and Retaining Access and Restoring Exclusivity (RARE) Act (118th, H.R. 7383 / S. 1214).
Policy issues related to federal regulation of the healthcare industry and rare diseases, including the Retaining Access and Restoring Exclusivity (RARE) Act (118th, H.R. 7383 / S. 1214).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 5029, 118th Congress).
Collegiate Freedom of Association Act
Client: FRATERNAL GOVERNMENT RELATIONS COALITION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to anti-hazing legislation, including support for the Stop Campus Hazing Act (H.R. 5646/S. 2901) and a resolution related to the designation of a National Hazing Awareness Week" (H.Res. 717/S.Res. 360). Issues related to freedom of association for members of collegiate student organizations, including support for Collegiate Freedom of Association Act (H.R. 1626) and Freedom of Association in Higher Education Act (H.R. 2451).
Collegiate Freedom of Association Act
Client: FRATERNAL GOVERNMENT RELATIONS COALITION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to anti-hazing legislation, including support for the Stop Campus Hazing Act (H.R. 5646/S. 2901) and a resolution related to the designation of a National Hazing Awareness Week" (H.Res. 1497/S.Res. 848). Issues related to freedom of association for members of collegiate student organizations, including support for Collegiate Freedom of Association Act (H.R. 1626), Freedom of Association in Higher Education Act (H.R. 2451), and freedom of association provisions in the Respecting the First Amendment on Campus Act (H.R. 7683) and the End Woke Higher Education Act (H.R. 3724).
Collegiate Freedom of Association Act
Client: FRATERNAL GOVERNMENT RELATIONS COALITION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to anti-hazing legislation, including support for the Stop Campus Hazing Act (P.L. 118-173) and a resolution related to the designation of a National Hazing Awareness Week" (H.Res. 1497/S.Res. 848). Issues related to freedom of association for members of collegiate student organizations, including support for Collegiate Freedom of Association Act (H.R. 1626), Freedom of Association in Higher Education Act (H.R. 2451), and freedom of association provisions in the Respecting the First Amendment on Campus Act (H.R. 7683) and the End Woke Higher Education Act (H.R. 3724).
Collegiate Freedom of Association Act
Client: FRATERNAL GOVERNMENT RELATIONS COALITION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to anti-hazing legislation, including support for the Stop Campus Hazing Act (H.R. 5646/S. 2901) and a resolution related to the designation of a National Hazing Awareness Week" (H.Res. 717/S.Res. 360). Issues related to freedom of association for members of collegiate student organizations, including support for Collegiate Freedom of Association Act (H.R. 1626), Freedom of Association in Higher Education Act (H.R. 2451), and freedom of association provisions in the Respecting the First Amendment on Campus Act (H.R. 7683).
Freedom of Association in Higher Education Act of 2023
Client: FRATERNAL GOVERNMENT RELATIONS COALITION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to anti-hazing legislation, including support for the Stop Campus Hazing Act (P.L. 118-173) and a resolution related to the designation of a National Hazing Awareness Week" (H.Res. 1497/S.Res. 848). Issues related to freedom of association for members of collegiate student organizations, including support for Collegiate Freedom of Association Act (H.R. 1626), Freedom of Association in Higher Education Act (H.R. 2451), and freedom of association provisions in the Respecting the First Amendment on Campus Act (H.R. 7683) and the End Woke Higher Education Act (H.R. 3724).
Freedom of Association in Higher Education Act of 2023
Client: FRATERNAL GOVERNMENT RELATIONS COALITION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to anti-hazing legislation, including support for the Stop Campus Hazing Act (H.R. 5646/S. 2901) and a resolution related to the designation of a National Hazing Awareness Week" (H.Res. 1497/S.Res. 848). Issues related to freedom of association for members of collegiate student organizations, including support for Collegiate Freedom of Association Act (H.R. 1626), Freedom of Association in Higher Education Act (H.R. 2451), and freedom of association provisions in the Respecting the First Amendment on Campus Act (H.R. 7683) and the End Woke Higher Education Act (H.R. 3724).
Freedom of Association in Higher Education Act of 2023
Client: FRATERNAL GOVERNMENT RELATIONS COALITION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to anti-hazing legislation, including support for the Stop Campus Hazing Act (H.R. 5646/S. 2901) and a resolution related to the designation of a National Hazing Awareness Week" (H.Res. 717/S.Res. 360). Issues related to freedom of association for members of collegiate student organizations, including support for Collegiate Freedom of Association Act (H.R. 1626) and Freedom of Association in Higher Education Act (H.R. 2451).
Freedom of Association in Higher Education Act of 2023
Client: FRATERNAL GOVERNMENT RELATIONS COALITION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to anti-hazing legislation, including support for the Stop Campus Hazing Act (H.R. 5646/S. 2901) and a resolution related to the designation of a National Hazing Awareness Week" (H.Res. 717/S.Res. 360). Issues related to freedom of association for members of collegiate student organizations, including support for Collegiate Freedom of Association Act (H.R. 1626), Freedom of Association in Higher Education Act (H.R. 2451), and freedom of association provisions in the Respecting the First Amendment on Campus Act (H.R. 7683).
Collegiate Housing and Infrastructure Act of 2023
Client: FRATERNAL GOVERNMENT RELATIONS COALITION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Tax issues related to non-profit student housing providers, including the Collegiate Housing and Infrastructure Act (H.R. 2662/S. 1420).
Collegiate Housing and Infrastructure Act of 2023
Client: FRATERNAL GOVERNMENT RELATIONS COALITION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Tax issues related to non-profit student housing providers, including the Collegiate Housing and Infrastructure Act (H.R. 2662/S. 1420).
Collegiate Housing and Infrastructure Act of 2023
Client: FRATERNAL GOVERNMENT RELATIONS COALITION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Tax issues related to non-profit student housing providers, including the Collegiate Housing and Infrastructure Act (H.R. 2662/S. 1420).
Collegiate Housing and Infrastructure Act of 2023
Client: FRATERNAL GOVERNMENT RELATIONS COALITION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Tax issues related to non-profit student housing providers, including the Collegiate Housing and Infrastructure Act (H.R. 2662/S. 1420).
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Legislation related to antikickback exclusions for travel and lodging arrangements between manufacturers of drugs and patients
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Legislation related to antikickback exclusions for travel and lodging arrangements between manufacturers of drugs and patients
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
End Woke Higher Education Act
Client: FRATERNAL GOVERNMENT RELATIONS COALITION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to anti-hazing legislation, including support for the Stop Campus Hazing Act (P.L. 118-173) and a resolution related to the designation of a National Hazing Awareness Week" (H.Res. 1497/S.Res. 848). Issues related to freedom of association for members of collegiate student organizations, including support for Collegiate Freedom of Association Act (H.R. 1626), Freedom of Association in Higher Education Act (H.R. 2451), and freedom of association provisions in the Respecting the First Amendment on Campus Act (H.R. 7683) and the End Woke Higher Education Act (H.R. 3724).
End Woke Higher Education Act
Client: FRATERNAL GOVERNMENT RELATIONS COALITION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to anti-hazing legislation, including support for the Stop Campus Hazing Act (H.R. 5646/S. 2901) and a resolution related to the designation of a National Hazing Awareness Week" (H.Res. 1497/S.Res. 848). Issues related to freedom of association for members of collegiate student organizations, including support for Collegiate Freedom of Association Act (H.R. 1626), Freedom of Association in Higher Education Act (H.R. 2451), and freedom of association provisions in the Respecting the First Amendment on Campus Act (H.R. 7683) and the End Woke Higher Education Act (H.R. 3724).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Stop Campus Hazing Act
Client: FRATERNAL GOVERNMENT RELATIONS COALITION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to anti-hazing legislation, including support for the Stop Campus Hazing Act (H.R. 5646/S. 2901) and a resolution related to the designation of a National Hazing Awareness Week" (H.Res. 717/S.Res. 360). Issues related to freedom of association for members of collegiate student organizations, including support for Collegiate Freedom of Association Act (H.R. 1626) and Freedom of Association in Higher Education Act (H.R. 2451).
Stop Campus Hazing Act
Client: FRATERNAL GOVERNMENT RELATIONS COALITION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to anti-hazing legislation, including support for the Stop Campus Hazing Act (H.R. 5646/S. 2901) and a resolution related to the designation of a National Hazing Awareness Week" (H.Res. 1497/S.Res. 848). Issues related to freedom of association for members of collegiate student organizations, including support for Collegiate Freedom of Association Act (H.R. 1626), Freedom of Association in Higher Education Act (H.R. 2451), and freedom of association provisions in the Respecting the First Amendment on Campus Act (H.R. 7683) and the End Woke Higher Education Act (H.R. 3724).
Stop Campus Hazing Act
Client: FRATERNAL GOVERNMENT RELATIONS COALITION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to anti-hazing legislation, including support for the Stop Campus Hazing Act (H.R. 5646/S. 2901) and a resolution related to the designation of a National Hazing Awareness Week" (H.Res. 717/S.Res. 360). Issues related to freedom of association for members of collegiate student organizations, including support for Collegiate Freedom of Association Act (H.R. 1626), Freedom of Association in Higher Education Act (H.R. 2451), and freedom of association provisions in the Respecting the First Amendment on Campus Act (H.R. 7683).
PLASMA Act
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access to plasma-derived products and implementation of the Inflation Reduction Act (IRA, P. L. 117-169), including the Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act (H.R. 6465 / S. 4741).
PLASMA Act
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access to plasma-derived products and implementation of the Inflation Reduction Act (IRA, P. L. 117-169), including the Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act (H.R. 6465).
PLASMA Act
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access to plasma-derived products and implementation of the Inflation Reduction Act (IRA, P. L. 117-169), including the Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act (H.R. 6465).
PLASMA Act
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access to plasma-derived products and implementation of the Inflation Reduction Act (IRA, P. L. 117-169), including the Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act (H.R. 6465 / S. 4741, 118th Congress).
Tax Relief for American Families and Workers Act of 2024
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to R&D tax credits, including the Tax Relief for American Families and Workers Act of 2024 (H.R. 7024).
Tax Relief for American Families and Workers Act of 2024
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to R&D tax credits, including the Tax Relief for American Families and Workers Act of 2024 (H.R. 7024).
Tax Relief for American Families and Workers Act of 2024
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to R&D tax credits, including the Tax Relief for American Families and Workers Act of 2024 (H.R. 7024).
Policy issues related to federal regulation of the healthcare industry and rare diseases, including the Retaining Access and Restoring Exclusivity (RARE) Act (H.R. 7383 / S. 1214, 118th Congress).
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Legislation related to antikickback exclusions for travel and lodging arrangements between manufacturers of drugs and patients
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Legislation related to antikickback exclusions for travel and lodging arrangements between manufacturers of drugs and patients
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Respecting the First Amendment on Campus Act
Client: FRATERNAL GOVERNMENT RELATIONS COALITION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to anti-hazing legislation, including support for the Stop Campus Hazing Act (H.R. 5646/S. 2901) and a resolution related to the designation of a National Hazing Awareness Week" (H.Res. 717/S.Res. 360). Issues related to freedom of association for members of collegiate student organizations, including support for Collegiate Freedom of Association Act (H.R. 1626), Freedom of Association in Higher Education Act (H.R. 2451), and freedom of association provisions in the Respecting the First Amendment on Campus Act (H.R. 7683).
Respecting the First Amendment on Campus Act
Client: FRATERNAL GOVERNMENT RELATIONS COALITION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to anti-hazing legislation, including support for the Stop Campus Hazing Act (P.L. 118-173) and a resolution related to the designation of a National Hazing Awareness Week" (H.Res. 1497/S.Res. 848). Issues related to freedom of association for members of collegiate student organizations, including support for Collegiate Freedom of Association Act (H.R. 1626), Freedom of Association in Higher Education Act (H.R. 2451), and freedom of association provisions in the Respecting the First Amendment on Campus Act (H.R. 7683) and the End Woke Higher Education Act (H.R. 3724).
Respecting the First Amendment on Campus Act
Client: FRATERNAL GOVERNMENT RELATIONS COALITION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to anti-hazing legislation, including support for the Stop Campus Hazing Act (H.R. 5646/S. 2901) and a resolution related to the designation of a National Hazing Awareness Week" (H.Res. 1497/S.Res. 848). Issues related to freedom of association for members of collegiate student organizations, including support for Collegiate Freedom of Association Act (H.R. 1626), Freedom of Association in Higher Education Act (H.R. 2451), and freedom of association provisions in the Respecting the First Amendment on Campus Act (H.R. 7683) and the End Woke Higher Education Act (H.R. 3724).
Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025
Client: WILLIAM & MARY FOUNDATION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to FY 2025 funding for the Troops to Teachers program, environmental forecasting, water quality monitoring, geospatial impact evaluations, and defense personnel workforce development, including as part of the National Defense Authorization Act (H.R. 8070) and FY 2025 LHHS, SFOPS (H.R. 8771), CJS (H.R. 9026), and Defense (H.R. 8774) appropriations bills.
Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025
Client: WILLIAM & MARY FOUNDATION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to FY 2025 funding for the Troops to Teachers program, environmental forecasting, water quality monitoring, geospatial impact evaluations, and defense personnel workforce development, including as part of the National Defense Authorization Act (H.R. 8070/S. 4638) and FY 2025 LHHS (H.R. 9029/S. 4942), SFOPS (H.R. 8771/S. 4797), CJS (H.R. 9026/S. 4795), and Defense (H.R. 8774/S. 4921) appropriations bills.
Department of State, Foreign Operations, and Related Programs Appropriations Act, 2025
Client: WILLIAM & MARY FOUNDATION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to FY 2025 funding for the Troops to Teachers program, environmental forecasting, water quality monitoring, geospatial impact evaluations, and defense personnel workforce development, including as part of the National Defense Authorization Act (H.R. 8070) and FY 2025 LHHS, SFOPS (H.R. 8771), CJS (H.R. 9026), and Defense (H.R. 8774) appropriations bills.
Department of State, Foreign Operations, and Related Programs Appropriations Act, 2025
Client: WILLIAM & MARY FOUNDATION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to FY 2025 funding for the Troops to Teachers program, environmental forecasting, water quality monitoring, geospatial impact evaluations, and defense personnel workforce development, including as part of the National Defense Authorization Act (P.L. 118-31) and FY 2025 LHHS (H.R. 9029/S. 4942), SFOPS (H.R. 8771/S. 4797), CJS (H.R. 9026/S. 4795), and Defense (H.R. 8774/S. 4921) appropriations bills.
Department of State, Foreign Operations, and Related Programs Appropriations Act, 2025
Client: WILLIAM & MARY FOUNDATION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to FY 2025 funding for the Troops to Teachers program, environmental forecasting, water quality monitoring, geospatial impact evaluations, and defense personnel workforce development, including as part of the National Defense Authorization Act (H.R. 8070/S. 4638) and FY 2025 LHHS (H.R. 9029/S. 4942), SFOPS (H.R. 8771/S. 4797), CJS (H.R. 9026/S. 4795), and Defense (H.R. 8774/S. 4921) appropriations bills.
Department of Defense Appropriations Act, 2025
Client: WILLIAM & MARY FOUNDATION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to FY 2025 funding for the Troops to Teachers program, environmental forecasting, water quality monitoring, geospatial impact evaluations, and defense personnel workforce development, including as part of the National Defense Authorization Act (P.L. 118-31) and FY 2025 LHHS (H.R. 9029/S. 4942), SFOPS (H.R. 8771/S. 4797), CJS (H.R. 9026/S. 4795), and Defense (H.R. 8774/S. 4921) appropriations bills.
Department of Defense Appropriations Act, 2025
Client: WILLIAM & MARY FOUNDATION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to FY 2025 funding for the Troops to Teachers program, environmental forecasting, water quality monitoring, geospatial impact evaluations, and defense personnel workforce development, including as part of the National Defense Authorization Act (H.R. 8070) and FY 2025 LHHS, SFOPS (H.R. 8771), CJS (H.R. 9026), and Defense (H.R. 8774) appropriations bills.
Department of Defense Appropriations Act, 2025
Client: WILLIAM & MARY FOUNDATION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to FY 2025 funding for the Troops to Teachers program, environmental forecasting, water quality monitoring, geospatial impact evaluations, and defense personnel workforce development, including as part of the National Defense Authorization Act (H.R. 8070/S. 4638) and FY 2025 LHHS (H.R. 9029/S. 4942), SFOPS (H.R. 8771/S. 4797), CJS (H.R. 9026/S. 4795), and Defense (H.R. 8774/S. 4921) appropriations bills.
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2025
Client: WILLIAM & MARY FOUNDATION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to FY 2025 funding for the Troops to Teachers program, environmental forecasting, water quality monitoring, geospatial impact evaluations, and defense personnel workforce development, including as part of the National Defense Authorization Act (H.R. 8070) and FY 2025 LHHS, SFOPS (H.R. 8771), CJS (H.R. 9026), and Defense (H.R. 8774) appropriations bills.
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2025
Client: WILLIAM & MARY FOUNDATION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to FY 2025 funding for the Troops to Teachers program, environmental forecasting, water quality monitoring, geospatial impact evaluations, and defense personnel workforce development, including as part of the National Defense Authorization Act (P.L. 118-31) and FY 2025 LHHS (H.R. 9029/S. 4942), SFOPS (H.R. 8771/S. 4797), CJS (H.R. 9026/S. 4795), and Defense (H.R. 8774/S. 4921) appropriations bills.
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2025
Client: WILLIAM & MARY FOUNDATION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to FY 2025 funding for the Troops to Teachers program, environmental forecasting, water quality monitoring, geospatial impact evaluations, and defense personnel workforce development, including as part of the National Defense Authorization Act (H.R. 8070/S. 4638) and FY 2025 LHHS (H.R. 9029/S. 4942), SFOPS (H.R. 8771/S. 4797), CJS (H.R. 9026/S. 4795), and Defense (H.R. 8774/S. 4921) appropriations bills.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: WILLIAM & MARY FOUNDATION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to FY 2025 funding for the Troops to Teachers program, environmental forecasting, water quality monitoring, geospatial impact evaluations, and defense personnel workforce development, including as part of the National Defense Authorization Act (H.R. 8070/S. 4638) and FY 2025 LHHS (H.R. 9029/S. 4942), SFOPS (H.R. 8771/S. 4797), CJS (H.R. 9026/S. 4795), and Defense (H.R. 8774/S. 4921) appropriations bills.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: WILLIAM & MARY FOUNDATION · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to FY 2025 funding for the Troops to Teachers program, environmental forecasting, water quality monitoring, geospatial impact evaluations, and defense personnel workforce development, including as part of the National Defense Authorization Act (P.L. 118-31) and FY 2025 LHHS (H.R. 9029/S. 4942), SFOPS (H.R. 8771/S. 4797), CJS (H.R. 9026/S. 4795), and Defense (H.R. 8774/S. 4921) appropriations bills.
Issues related to HRSA's regulation of cord blood storage and the Stem Cell Therapeutic and Research Reauthorization Act (H.R. 5160/S. 4109).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALBRIGHT COLLEGE via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · Q3
Issues related to higher education, distance learning, federal student aid and Pell Grants, artificial intelligence, Workforce Pell, and workforce policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SUMITOMO PHARMA AMERICA, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · Q3
Issues related to prescription drug pricing, and issues related to small to mid-size pharmaceutical companies.
Issues related to prescription drug pricing, and issues related to small to mid-size pharmaceutical companies.
Filing targets: SENATE
RECORDATI RARE DISEASES INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · Q3
Issues related to improving access to needed therapies for rare and ultra-rare diseases in the United States. Issues related to drug pricing, including most favored nation (MFN) policies.
Issues related to trade and tariff policies pertaining to therapies for rare and ultra-rare diseases in the United States.
Issues related to improving access to needed therapies for rare and ultra-rare diseases in the United States. Issues related to drug pricing, including most favored nation (MFN) policies.
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · Q3
Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding.
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Issues related to general compounding.
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · Q3
Issues related to regulatory incentives for rare disease therapies.
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
UNICYCIVE THERAPEUTICS INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · Q3
Issue related to kidney disease therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · Q3
Outreach related to drug pricing policies, including patent and intellectual property issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEURALINK CORP. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · Q3
Issues related to access to medical devices, including neurotechnology/brain-computer interface products.
Issues related to Medicare coverage and reimbursement pathways for breakthrough medical devices.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, White House Office
ESTEVE PHARMACEUTICALS, LLC via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · Q3
Issues related to reimbursement and coverage for certain drugs.
Issues related to reimbursement and coverage for certain drugs.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · Q3
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNICYCIVE THERAPEUTICS INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · RR
Issue related to kidney disease therapeutics.
NEURALINK CORP. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · Q2
Issues related to access to medical devices, including neurotechnology/brain-computer interface products.
Issues related to Medicare coverage and reimbursement pathways for breakthrough medical devices.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · Q2
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ESTEVE PHARMACEUTICALS, LLC via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · Q2
Issues related to reimbursement and coverage for certain drugs.
Issues related to reimbursement and coverage for certain drugs.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
CALBRIGHT COLLEGE via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · Q2
Issues related to higher education, distance learning, federal student aid and Pell Grants, artificial intelligence, Workforce Pell, and workforce policy.
Filing targets: Education, Dept of, HOUSE OF REPRESENTATIVES, SENATE
SPYRE THERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · Q2
Issues related to monoclonal antibody products.
Filing targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
NEW YORK BLOOD CENTER ENTERPRISES via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · Q2
Issues related to HRSA's regulation of cord blood storage and the Stem Cell Therapeutic and Research Reauthorization Act (HR5160/S4109).
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
SUMITOMO PHARMA AMERICA, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · Q2
Issues related to prescription drug pricing, and issues related to small to mid-size pharmaceutical companies.
Issues related to prescription drug pricing, and issues related to small to mid-size pharmaceutical companies.
RECORDATI RARE DISEASES INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · Q2
Issues related to improving access to needed therapies for rare and ultra-rare diseases in the United States. Issues related to drug pricing, including most favored nation (MFN) policies.
Issues related to improving access to needed therapies for rare and ultra-rare diseases in the United States. Issues related to drug pricing, including most favored nation (MFN) policies.
Issues related to trade and tariff policies pertaining to therapies for rare and ultra-rare diseases in the United States.
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · Q2
Issues related to general compounding.
Issues related to general compounding.
Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding.
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · Q2
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Issues related to regulatory incentives for rare disease therapies.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NEURALINK CORP. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · RR
Issues related to the development and commercialization of brain-computer interfaces.
SPYRE THERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · Q1
Issues related to monoclonal antibody products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEW YORK BLOOD CENTER ENTERPRISES via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · Q1
Issues related to HRSA's regulation of cord blood storage.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALBRIGHT COLLEGE via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · Q1
Issues related to higher education, distance learning, federal student aid and Pell Grants, artificial intelligence, and workforce policy.
Issues related to federal funding for employment pathways in FY 2027 LHHS appropriations bill.
Filing targets: Education, Dept of, HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · Q1
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ESTEVE PHARMACEUTICALS, LLC via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · Q1
Issues related to reimbursement and coverage for certain drugs.
Issues related to reimbursement and coverage for certain drugs.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
NEURELIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · Q1
Policy issues related to federal regulation of the healthcare industry and rare diseases, including the Give Kids a Chance Act (119th, H.R. 1262 / S. 932) and the Retaining Access and Restoring Exclusivity (RARE) Act (118th, H.R. 7383 / S. 1214).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SUMITOMO PHARMA AMERICA, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · Q1
Issues related to prescription drug pricing, and issues related to small to mid-size pharmaceutical companies.
Issues related to prescription drug pricing, and issues related to small to mid-size pharmaceutical companies.
RECORDATI RARE DISEASES INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · Q1
Issues related to improving access to needed therapies for rare and ultra-rare diseases in the United States. Issues related to drug pricing, including most favored nation (MFN) policies.
Issues related to trade and tariff policies pertaining to therapies for rare and ultra-rare diseases in the United States.
Issues related to improving access to needed therapies for rare and ultra-rare diseases in the United States. Issues related to drug pricing, including most favored nation (MFN) policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · Q1
Issues related to general compounding.
Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding.
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · Q1
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Issues related to regulatory incentives for rare disease therapies.
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NEW YORK BLOOD CENTER ENTERPRISES via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · RR
Issues related to cord blood storage.
SUMITOMO PHARMA AMERICA, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · RR
Issues related to prescription drug pricing, and issues related to small to mid-size pharmaceutical companies.
Issues related to prescription drug pricing, and issues related to small to mid-size pharmaceutical companies.
ESTEVE PHARMACEUTICALS, LLC via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · RR
Issues related to reimbursement and coverage for certain drugs.
Issues related to reimbursement and coverage for certain drugs.
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · fourth_quarter · Q4
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALBRIGHT COLLEGE via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · fourth_quarter · Q4
Issues related to higher education, distance learning, federal student aid and Pell Grants, artificial intelligence, and workforce policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPYRE THERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · fourth_quarter · Q4
Issues related to monoclonal antibody products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RECORDATI RARE DISEASES INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · fourth_quarter · Q4
Issues related to improving access to needed therapies for rare and ultra-rare diseases in the United States. Issues related to drug pricing, including most favored nation (MFN) policies.
Issues related to improving access to needed therapies for rare and ultra-rare diseases in the United States. Issues related to drug pricing, including most favored nation (MFN) policies.
Issues related to trade and tariff policies pertaining to therapies for rare and ultra-rare diseases in the United States.
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · fourth_quarter · Q4
Issues related to general compounding.
Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding.
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · fourth_quarter · Q4
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPYRE THERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · fourth_quarter · RR
FDA policies relating to monoclonal antibody products.
FDA policies relating to monoclonal antibody products.
FDA policies relating to monoclonal antibody products.
RECORDATI RARE DISEASES INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · fourth_quarter · RR
Issues related to improving access to needed therapies for rare and ultra-rare diseases in the U.S.
Issues related to improving access to needed therapies for rare and ultra-rare diseases in the U.S.
Issues related to improving access to needed therapies for rare and ultra-rare diseases in the U.S.
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · third_quarter · Q3
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program. Issues related to biopharmaceutical intellectual property and patent matters.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALBRIGHT COLLEGE via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · third_quarter · Q3
Issues related to higher education, distance learning, federal student aid and Pell Grants, artificial intelligence, and workforce policy.
Filing targets: Education, Dept of, HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · third_quarter · Q3
Issues related to the 340B Program. Issues related to general compounding.
Issues related to the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding.
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · third_quarter · Q3
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · second_quarter · Q2
Issues related to pharmacy benefit managers (PBMs). Issues related to the 340B Program. Issues related to general compounding.
Issues related to pharmacy benefit managers (PBMs) and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding.
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
NEURELIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · second_quarter · Q2
Policy issues related to federal regulation of the healthcare industry and rare diseases, including the Give Kids a Chance Act (119th, H.R. 1262 / S. 932) and Retaining Access and Restoring Exclusivity (RARE) Act (118th, H.R. 7383 / S. 1214).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · second_quarter · Q2
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program. Issues related to biopharmaceutical intellectual property and patent matters.
Issues related to research and development (R&D) tax credits.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · second_quarter · Q2
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALBRIGHT COLLEGE via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · second_quarter · Q2
Issues related to higher education, distance learning, federal student aid and Pell Grants, and workforce policy, including the One Big Beautiful Bill Act (P.L. 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · first_quarter · Q1
Issues related to pharmacy benefit managers (PBMs) and the 340B Program.
Issues related to pharmacy benefit managers (PBMs) and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability.
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · first_quarter · Q1
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 5029, 118th Congress).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program. Issues related to biopharmaceutical intellectual property and patent matters.
Issues related to research and development (R&D) tax credits.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK A/S via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · first_quarter · Q1
Issues related to manufacturing capacity and supply chain resiliency.
Issues related to manufacturing capacity and supply chain resiliency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEURELIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · first_quarter · Q1
Policy issues related to federal regulation of the healthcare industry and rare diseases, including the Retaining Access and Restoring Exclusivity (RARE) Act (118th, H.R. 7383 / S. 1214).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · first_quarter · Q1
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WILLIAM & MARY FOUNDATION via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · first_quarter · Q1
Issues related to higher education policy, research, and development, including student financial aid, career development, teacher preparation, student veterans, legal support for veterans, coastal systems, and democracy reform.
Issues related to funding for the Troops to Teachers program, environmental forecasting, water quality monitoring, geospatial impact evaluations, and defense personnel workforce development, including as part of the FY 2025 Continuing Resolution (P.L. 119-4). Issues related to FY 2026 LHHS, SFOPS, CJS, and Defense appropriations bills.
Filing targets: Army, Dept of (Other), HOUSE OF REPRESENTATIVES, Natl Oceanic & Atmospheric Administration (NOAA), SENATE
CALBRIGHT COLLEGE via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · first_quarter · Q1
Issues related to higher education, distance learning, and workforce policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FRATERNAL GOVERNMENT RELATIONS COALITION via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · Q4
Tax issues related to non-profit student housing providers, including the Collegiate Housing and Infrastructure Act (H.R. 2662/S. 1420).
Issues related to anti-hazing legislation, including support for the Stop Campus Hazing Act (P.L. 118-173) and a resolution related to the designation of a National Hazing Awareness Week" (H.Res. 1497/S.Res. 848). Issues related to freedom of association for members of collegiate student organizations, including support for Collegiate Freedom of Association Act (H.R. 1626), Freedom of Association in Higher Education Act (H.R. 2451), and freedom of association provisions in the Respecting the First Amendment on Campus Act (H.R. 7683) and the End Woke Higher Education Act (H.R. 3724).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · Q4
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 5029, 118th Congress).
Issues related to biopharmaceutical intellectual property and patent matters.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program, including the Bipartisan 340B Senate Working Group's discussion draft of the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act). Issues related to biopharmaceutical intellectual property and patent matters.
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · Q4
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
PHARMAESSENTIA USA CORPORATION via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · Q4
Issues related to implementation of the Inflation Reduction Act (IRA, P.L. 117-169).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK A/S via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · Q4
Issues related to manufacturing capacity and supply chain resiliency.
Issues related to manufacturing capacity and supply chain resiliency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · Q4
Issues related to pharmacy benefit managers (PBMs) and the 340B Program.
Issues related to pharmacy benefit managers (PBMs) and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability.
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEURELIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · Q4
Policy issues related to federal regulation of the healthcare industry and rare diseases, including the Retaining Access and Restoring Exclusivity (RARE) Act (H.R. 7383 / S. 1214, 118th Congress).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · 4T
Issues related to access to plasma-derived products and implementation of the Inflation Reduction Act (IRA, P. L. 117-169), including the Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act (H.R. 6465 / S. 4741, 118th Congress).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WILLIAM & MARY FOUNDATION via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · Q4
Issues related to FY 2025 funding for the Troops to Teachers program, environmental forecasting, water quality monitoring, geospatial impact evaluations, and defense personnel workforce development, including as part of the National Defense Authorization Act (P.L. 118-31) and FY 2025 LHHS (H.R. 9029/S. 4942), SFOPS (H.R. 8771/S. 4797), CJS (H.R. 9026/S. 4795), and Defense (H.R. 8774/S. 4921) appropriations bills.
Issues related to higher education policy, research, and development, including student financial aid, career development, teacher preparation, student veterans, legal support for veterans, coastal systems, and democracy reform.
Filing targets: Army, Dept of (Other), HOUSE OF REPRESENTATIVES, Natl Oceanic & Atmospheric Administration (NOAA), SENATE
CALBRIGHT COLLEGE via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · Q4
Issues related to higher education, distance learning, and workforce policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEURELIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · RR
Policy issues related to federal regulation of the healthcare industry.
Policy issues related to federal regulation of the healthcare industry.
PHARMAESSENTIA USA CORPORATION via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · Q3
Issues related to implementation of the Inflation Reduction Act (IRA, P.L. 117-169).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · Q3
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 5029).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program, including the Bipartisan 340B Senate Working Group's discussion draft of the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act). Issues related to biopharmaceutical intellectual property and patent matters.
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · Q3
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
FRATERNAL GOVERNMENT RELATIONS COALITION via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · Q3
Tax issues related to non-profit student housing providers, including the Collegiate Housing and Infrastructure Act (H.R. 2662/S. 1420).
Issues related to anti-hazing legislation, including support for the Stop Campus Hazing Act (H.R. 5646/S. 2901) and a resolution related to the designation of a National Hazing Awareness Week" (H.Res. 1497/S.Res. 848). Issues related to freedom of association for members of collegiate student organizations, including support for Collegiate Freedom of Association Act (H.R. 1626), Freedom of Association in Higher Education Act (H.R. 2451), and freedom of association provisions in the Respecting the First Amendment on Campus Act (H.R. 7683) and the End Woke Higher Education Act (H.R. 3724).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · Q3
Issues related to pharmacy benefit managers (PBMs) and the 340B Program.
Issues related to pharmacy benefit managers (PBMs) and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability.
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
NOVO NORDISK A/S via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · Q3
Issues related to manufacturing capacity and supply chain resiliency.
Issues related to manufacturing capacity and supply chain resiliency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · Q3
Issues related to access to plasma-derived products and implementation of the Inflation Reduction Act (IRA, P. L. 117-169), including the Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act (H.R. 6465 / S. 4741).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WILLIAM & MARY FOUNDATION via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · Q3
Issues related to FY 2025 funding for the Troops to Teachers program, environmental forecasting, water quality monitoring, geospatial impact evaluations, and defense personnel workforce development, including as part of the National Defense Authorization Act (H.R. 8070/S. 4638) and FY 2025 LHHS (H.R. 9029/S. 4942), SFOPS (H.R. 8771/S. 4797), CJS (H.R. 9026/S. 4795), and Defense (H.R. 8774/S. 4921) appropriations bills.
Issues related to higher education policy, research, and development, including student financial aid, career development, teacher preparation, student veterans, legal support for veterans, coastal systems, and democracy reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALBRIGHT COLLEGE via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · Q3
Issues related to higher education, distance learning, and workforce policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMAESSENTIA USA CORPORATION via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · RA
Issues related to implementation of the Inflation Reduction Act (IRA, P. L. 117-169).
PHARMAESSENTIA USA CORPORATION via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · RR
Issues related to implementation of the Inflation Reduction Act (IRA, P. L. 117-169).
NOVO NORDISK A/S via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues related to manufacturing capacity and supply chain resiliency.
Issues related to manufacturing capacity and supply chain resiliency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues related to access to plasma-derived products and implementation of the Inflation Reduction Act (IRA, P. L. 117-169), including the Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act (H.R. 6465).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERRIGO COMPANY PLC via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues related to the manufacturing of infant formula.
Issues related to the manufacturing of infant formula and issues related to over-the-counter birth control.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program, including the Bipartisan 340B Senate Working Group's discussion draft of the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act).
Issues related to R&D tax credits, including the Tax Relief for American Families and Workers Act of 2024 (H.R. 7024).
ENDEAVORS via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues related to policy issues relating to migrant services.
Issues related to CBP wellness and FEMA disaster case management.
Issues related to FY 25 appropriations regarding veterans' housing and supportive services, CBP wellness, disaster case management, and Continuum of Care.
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Legislation related to antikickback exclusions for travel and lodging arrangements between manufacturers of drugs and patients
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Legislation related to antikickback exclusions for travel and lodging arrangements between manufacturers of drugs and patients
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
FRATERNAL GOVERNMENT RELATIONS COALITION via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues related to anti-hazing legislation, including support for the Stop Campus Hazing Act (H.R. 5646/S. 2901) and a resolution related to the designation of a National Hazing Awareness Week" (H.Res. 717/S.Res. 360). Issues related to freedom of association for members of collegiate student organizations, including support for Collegiate Freedom of Association Act (H.R. 1626), Freedom of Association in Higher Education Act (H.R. 2451), and freedom of association provisions in the Respecting the First Amendment on Campus Act (H.R. 7683).
Tax issues related to non-profit student housing providers, including the Collegiate Housing and Infrastructure Act (H.R. 2662/S. 1420).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Issues related to pharmacy benefit managers and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications.
Issues related to pharmacy benefit managers and the 340B Program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
WILLIAM & MARY FOUNDATION via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues related to FY 2025 funding for the Troops to Teachers program, environmental forecasting, water quality monitoring, geospatial impact evaluations, and defense personnel workforce development, including as part of the National Defense Authorization Act (H.R. 8070) and FY 2025 LHHS, SFOPS (H.R. 8771), CJS (H.R. 9026), and Defense (H.R. 8774) appropriations bills.
Issues related to higher education policy, research, and development, including student financial aid, career development, teacher preparation, student veterans, coastal systems, and democracy reform.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Oceanic & Atmospheric Administration (NOAA), SENATE
CALBRIGHT COLLEGE via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues related to higher education, online learning, and workforce policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK A/S via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · RR
Manufacturing capacity and supply chain resiliency.
Manufacturing capacity and supply chain resiliency.
PERRIGO COMPANY PLC via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · first_quarter · Q1
Issues related to the manufacturing of infant formula and issues related to over-the-counter birth control.
Issues related to the manufacturing of infant formula.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · first_quarter · Q1
Issues related to R&D tax credits, including the Tax Relief for American Families and Workers Act of 2024 (H.R. 7024).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program, including the Bipartisan 340B Senate Working Group's discussion draft of the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation.
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · first_quarter · Q1
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · first_quarter · Q1
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Issues related to pharmacy benefit managers and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications.
Issues related to pharmacy benefit managers and the 340B Program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
FRATERNAL GOVERNMENT RELATIONS COALITION via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · first_quarter · Q1
Tax issues related to non-profit student housing providers, including the Collegiate Housing and Infrastructure Act (H.R. 2662/S. 1420).
Issues related to anti-hazing legislation, including support for the Stop Campus Hazing Act (H.R. 5646/S. 2901) and a resolution related to the designation of a National Hazing Awareness Week" (H.Res. 717/S.Res. 360). Issues related to freedom of association for members of collegiate student organizations, including support for Collegiate Freedom of Association Act (H.R. 1626) and Freedom of Association in Higher Education Act (H.R. 2451).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDEAVORS via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · first_quarter · Q1
Issues related to veterans medical, housing, and assistance services.
CBP wellness and FEMA disaster case management.
FY 24 appropriations regarding veterans' housing and supportive services, disaster case management; FY 25 appropriations regarding veterans' housing and supportive services, CBP wellness, disaster case management, and Continuum of Care.
Issues related to general compounding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to general compounding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to general compounding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to general compounding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to general compounding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to research and development (R&D) tax credits.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to biopharmaceutical intellectual property and patent matters.
Issues related to R&D tax credits, including the Tax Relief for American Families and Workers Act of 2024 (H.R. 7024).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to veterans medical, housing, and assistance services.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Policy issues relating to migrant services.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE